The top 10 biopharma stock gainers and losers for the week.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apyx Medical, Intuitive Surgical.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott, CSI, Checkable Medical, Globus Medical, Greenlight Guru, HTEC Group, Nuvasive, Precipio, Proteomedix.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Xeltis.

Med-tech firms raising money in public or private financings, including: Genedx.

Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amicus, BMS, Editas, Eli Lilly, Gensight, GSK, Intelgenx, Novartis, Ocugen, Roche, Seres, Taiho, Takeda.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amgen, Openbench, Provention, Sanofi, Tavros.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Alnylam, Amphera, Avacta, Biocryst, Bionomics, Celularity, Cinrx, Clearside, Elicio, Galapagos, Junshi, Lilly, Minoryx, Nexcella, Palatin, Regeneron, Skye.